• Bone Health
  • Immunology
  • Hematology
  • Respiratory
  • Dermatology
  • Diabetes
  • Gastroenterology
  • Neurology
  • Oncology
  • Ophthalmology
  • Rare Disease
  • Rheumatology

Bio-Thera Begins Phase 1 Study of Proposed Golimumab Biosimilar

Article

Bio-Thera Solutions, a global biotechnology company based in Guangzhou, China, says it began a phase 1 study of BAT2506, a proposed golimumab biosimilar referencing Simponi.

Bio-Thera Solutions, a global biotechnology company based in Guangzhou, China, says it began a phase 1 study of BAT2506, a proposed golimumab biosimilar referencing Simponi.

The study compares the pharmacokinetics and safety of BAT2506 to golimumab sourced from the European Union, with each participant receiving either a single subcutaneous dose of BAT2506 or golimumab. The randomized, double-blind, 2-arm, parallel group study is expected to enroll about 182 healthy volunteers.

“Initiating our [phase 1] clinical trial for BAT2506, our proposed biosimilar for Simponi, represents the fourth biosimilar that Bio-Thera has advanced into clinical trials,” said Shengfeng Li, chief executive office of Bio-Thera Solutions, in a statement. “Bio-Thera is committed to bringing safe and effective biosimilars to patients around the world.”

The brand-name Simponi, developed by Janssen, is FDA approved to treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis (AS), and ulcerative colitis. An anti—tumor necrosis factor therapy, golimumab is administered via a subcutaneous injection. Another formulation of golimumab, sold as Simponi Aria, is available for intravenous infusion.

Worldwide, Janssen saw sales of $563 million from the 2 formulations of Simponi, up 2.7% from the same quarter in 2018.

Bio-Thera Solutions is also developing other proposed biosimilars. Its proposed adalimumab biosimilar, BAT1406, recently met its primary end point of equivalent efficacy to reference adalimumab, Humira, in a phase 3 trial conducted in patients with active AS.

It is also developing a proposed bevacizumab biosimilar, BAT1706, referencing Avastin, and BAT1806, a proposed tocilizumab (Actemra) biosimilar. BAT1806 is also in a phase 3 trial.

Recent Videos
Sophia Humphreys, PharmD
Lakesha Farmer from Cencora
Prerakkumar Parikh, PharmD
Chelsee Jensen, PharmD, BCPS
GBW 2023 webinar
Fran Gregory, PharmD, MBA
Julie Reed
Julie Reed, executive director of the Biosimilars Forum
Fran Gregory, PharmD, vice president of emerging therapies, Cardinal Health
Here are the top 5 biosimilar articles for the week of May 1, 2023.
Related Content
© 2024 MJH Life Sciences

All rights reserved.